Stock Financial Ratios, Dividends, Split History

BANC / Banc of California, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)11.05
Enterprise Value ($M)-162.51
Book Value ($M)993.76
Book Value / Share1,712.59
Price / Book0.01
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Shares Outstanding 508,107
Weighted Average Number Of Shares Outstanding Basic 50,254,595
Weighted Average Number Of Diluted Shares Outstanding 50,819,790
Common Shares Outstanding2 50,083,262
Scoring Models
Piotroski F-Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.06
Return on Assets (ROA)0.01
Return on Equity (ROE)0.06
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Disposal Group Including Discontinued Operation Brokerage Commissions Revenue0.00
Net Income57.71
Earnings Per Share Diluted0.71
Earnings Per Share Basic0.72
Cash Flow Statement (mra) ($M)
Cash From Operations563.01
Cash from Investing151.86
Cash from Financing151.86
Identifiers and Descriptors
Central Index Key (CIK)1169770

Split History

Stock splits are used by Banc of California, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Banc Of California Putting Its History Behind It

2018-05-17 seekingalpha
Banc of California (BANC) is a southern California regional bank with a market cap of $940 million and assets of just over $10 billion. The stock has been written about on SA and other places a number of times over the past few years, but now that the recent overhangs are moving into the rear-view mirror, I wanted to circle back and check on the company. (2-1)

Banc of California's (BANC) CEO Doug Bowers on Q1 2018 Results - Earnings Call Transcript

2018-04-28 seekingalpha
Banc of California, Inc. (NYSE:BANC) Q1 2018 Earnings Conference Call April 27, 2018 10:00 AM ET (2-0)

Banc of California, Inc. 2018 Q1 - Results - Earnings Call Slides

2018-04-27 seekingalpha
The following slide deck was published by Banc of California, Inc. in conjunction with their 2018 Q1 earnings call. (2-0)

Top Analyst Upgrades and Downgrades: ADM, Boeing, Hess, LogMeIn, NetApp, Sunrun, United Continental, Valeant, XPO and More

2018-04-06 247wallst
Stocks were weak on Friday morning ahead of the unemployment and payrolls report, due to an expanded potential of $100 billion more in tariffs against China. The market has been swinging up and down, the bull market is now over nine years old, and the trend of buying pullbacks has become much more vulnerable to sellers and volatility trades. All this is making it harder for investors to decide how they want their assets positioned for the rest of 2018 and beyond. (134-1)

BRIEF-Banc Of California - Co And Its Unit, Concluded That Bank Will Record $13.7 Mln Specific Loan Loss Provision​

2018-03-15 reuters